IBD: Ustekinumab shows promise in the treatment of refractory Crohn's disease

Nature Reviews Gastroenterology and Hepatology

Volumn 9, Issue 12, 2012, Pages 690-

  Ray, Katrina ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 23; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB;

BASAL CELL CARCINOMA; CARDIOVASCULAR DISEASE; CROHN DISEASE; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; HUMAN; MAINTENANCE THERAPY; NOTE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PSORIASIS; REMISSION;

EID: 84870602035     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2012.213     Document Type: Note

References (1)

1. Sandborn, W. J. et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N. Engl. J. Med. 367, 1519-1528 (2012)